JPH072688A - Enterotoxic putrescent product inhibitor - Google Patents

Abstract

PURPOSE:To suppress toxic putrescent substances produced in the intestine due to esp. excessive intake of animal proteins by administering mushroom extract. CONSTITUTION:Mushroom extract has such effect as to suppress amines or mercaptans as the toxic putrescent substances produced in the intestine. This is suggested by reduction (to zero) of the serum levels of tryptamine and/or indole, metabolite(s) of tryptophan rich in animal proteins, by administering such extract. Therefore, administration of mushroom extract can prevent adult diseases including gastrointestinal lesions and hepatopathy which have been rapidly increasing in recent years due to excessive intake of animal proteins.

Description

DETAILED DESCRIPTION OF THE INVENTION <Industrial field of application> The present invention relates to a preparation for the purpose of suppressing and preventing the production of intestinal toxic spoilage products.

<Prior Art> In recent years, westernized dietary habits have increased the incidence of colon cancer. It is thought that this is due to changes in dietary content. Firstly, the intake of animal protein and high fat increased, and secondly, the intake of dietary fiber decreased. When food is ingested, it is converted into nutrients that are easily absorbed by enzymes in the digestive tract, but on the other hand, the degradation by intestinal bacteria changes the protein into various amines and mercaptans that are one of the decay products. Many amines and mercaptans are toxic, and certain amino acid degradation products are carcinogenic, and it is considered that these are produced by intestinal harmful bacteria. In addition, the produced spoilage product inhibits the absorption of nutrients in the intestine and is absorbed from the capillaries of the intestinal wall, which has various adverse effects on the living body. Conventionally,
As a method of suppressing intestinal spoilage products, a method of killing malignant intestinal bacteria such as Escherichia coli, Clostridium perfringens, and Salmonella that produce harmful substances in the intestine by administering antibiotics has been used. However, it is often reported that heavy use of antibiotics kills useful bacteria in the intestine, produces resistant bacteria, disrupts the intestinal flora, and causes a decrease in immune function. It is also effective to ingest mainly foods rich in dietary fiber to make useful bacteria in the intestine dominant and reduce harmful bacteria involved in the production of harmful substances. Continuing the diet of therapy is painful and bland. It is ideal to have a good dietary intake of animal and plant nutrients, and it has been reported that excessive intake of dietary fiber impairs the absorption of trace metals such as iron, copper and calcium required by the body. .

<Problems to be Solved by the Invention> An object of the present invention is to provide a mushroom for which humans normally eat the development of intestinal toxic spoilage products caused by excessive intake of animal protein and high lipid vesicles due to westernization of diet. It is to suppress or prevent by orally administering the extract extracted from the fruiting body. Another object of the present invention is to suppress or prevent intestinal development of spoilage products by adding to foods, beverages, feeds, etc. and continuously ingesting them. Studies on the physiologically active effect of mushrooms have also been carried out, and their inhibitory effects on mouse meat species have been reported.

<Means for Solving the Problem> The above object is achieved by an extract (Bio-M manufactured by Recom Co., Ltd.) extracted from a mushroom fruiting body with an aqueous solution. Mushroom fruiting bodies that can be used in the present invention are organic fertilizers produced by fermenting a mixture of straw, chicken manure, cottonseed oil dregs, etc. at 60-70 ° C to grow thermophilic fungi at 40-55 ° C. After composting mushroom compost at 25 ℃ with increased content of protein (protein) and growing mycelia, cover with what was kneaded with peat moss, red soil, water, etc., temperature 15 ℃, humidity 7
It is a uniform product obtained by forming fruiting bodies under the condition of 0 to 80%. The fruit body can use any of the umbrella part, the handle part and the root part. The growth period is preferably one when the umbrella is not opened so often. The freshness is as good as new,
When storing, it is necessary to refrigerate or freeze at 0 to 5 ° C. Extraction is performed by adding 150 parts to 500 parts of an aqueous organic acid solution having a pH of 4 to 6 to 100 parts of fruiting body, gradually raising the temperature from cold water, and when a certain temperature is reached, immediately filtering to obtain a supernatant. . As the organic acid, malic acid, citric acid, succinic acid, acetic acid and the like can be used.

<Action / Effect> By orally administering the product of the present invention, it is possible to suppress or prevent the generation of toxic spoilage products produced by intestinal harmful bacteria. This is suggested by the combined administration of the product of the present invention and tryptophan, whereby the tryptophan metabolites, tryptamine and indole are reduced or eliminated in the serum. Tryptophan is an essential amino acid contained in animal proteins rather than in dietary proteins in a relatively large amount, and produces tryptamine and indole by decarboxylation reaction and enterobacteria. These tryptophan metabolites, tryptamine and indole, are known as harmful substances of the body with a unique malodor, and are produced in large amounts in the intestine depending on the content of food intake, and part of them are absorbed to start gastrointestinal and liver function. And various damages to blood vessels. By ingesting the product of the present invention, suppress or prevent various tryptophan metabolites produced in the intestine when food is ingested, thereby,
It is considered to prevent adult diseases including gastrointestinal and liver disorders, which have been rapidly increasing due to changes in diet in recent years. The specific compound involved in the mechanism of action of the product of the present invention has not been identified so far, but it does not originally exist in mushrooms, and the enzyme system of mushroom cells is involved in the extraction process, It is considered that the compound is produced in.

<Examples> (1) Manufacturing method (Bio-M manufacturing method manufactured by Recom) 1 kg of fresh mushroom fruit bodies was sliced into 1.
7 kg of 0.5% malic acid aqueous solution is added, and the temperature is gradually raised with occasional stirring, and the mixture is heated at 70 ° C. for 1 to 2 hours. Then, it was immediately filtered with a filter to obtain 2 kg of the extract of the present invention.

(2) Administration test method Rabbit (Japanese white native species) male, weight 2.0-2.5k
g is divided into (1) tryptophan administration group, (2) combination administration group of tryptophan and the product of the present invention, (3) control group (tryptophan non-administration group), and each is orally administered using catether, tryptophan and tryptophan The concentration of metabolites in serum was observed. The dose of tryptophan was 1 g per kg of body weight by suspending L-tryptophan in distilled water. The dose of the product of the present invention is 1 kg body weight
It was set to 5 ml per one. Blood was collected from the ear vein before administration of the product of the present invention and 1, 3, 6, 9, 12 hours after administration, and immediately serum was separated at 3,000 rpm 10 '. H
The analysis conditions of PLC were as follows. HPLC: VAR
IAN5000 column: Hitachi Gel # 30
56 (4 mm x 150 mm), movement: Trifluov
Oacetic acid (TFA) 0.1%, Ace
tonitolile 15.0%, D, W84.9%,
Flow rate: 1.0 ml / min, detector: UV265 nm.
For the feeding (solid feed ORC4 manufactured by Oriental Yeast Co., Ltd.) and water, the test plot and the control plot were freely taken.

<Test Example> (1) Test Example: Change of Tryptophan in Serum Over Time Tables (1) and (2) of Table 1 show numerical values in serum after oral administration of tryptophan. One hour after the administration, the serum levels of the tryptophan-administered group in which the tryptophan and the product of the present invention were administered were higher than those in the tryptophan-only group, suggesting that the digestive absorption rate of tryptophan in the small intestine is positively affected. In addition, 6 hours later, the group of the present invention combined administration,
A significant difference in the decomposition of tryptophan was found as compared with the single administration group, and the values shown in Table 1- (3) were close to those of the control group. Generally, most of the ingested protein is decomposed into amino acids by digestive enzymes in the small intestine and then absorbed.
Proteins not absorbed in the small intestine are sent to the large intestine,
It is thought to be decomposed by putrefactive bacteria to produce various toxic substances with carcinogenicity. Also, the absorbed amino acids are resynthesized again by the action of the liver to form a protein. Therefore, it is considered that the value of the combined administration group after 6 hours has a good effect on the promotion of protein resynthesis in the liver by the product of the present invention.

(2) Test Example: Change with time of indole in serum Tables 2- (1) and (2) show changes with time of indole in serum. 1-12 after administration of tryptophan alone
A large amount of indole is found in the serum after the passage of time. Compared with this, in the combined administration group, a decreasing tendency was observed over time,
After 12 hours, indole in the serum was not seen as in the control group in Table 2- (3).

(3) Test example: Change in tryptamine in serum over time Table 3
-(1) and (2) show changes with time of tryptamine in serum. In the tryptophan single administration group, a large amount of tryptamine is generated in the serum after 1 to 6 hours have elapsed. In contrast to this, in the combination administration group, the production of tryptamine was not seen, as in the control group in Table 3- (3).

<Effect of the invention> The harmful substance produced in the intestine enters the blood vessel and can be seen in the serum. By the combined administration of the product of the present invention and tryptophan, oral tryptophan oral administration usually showed a tendency to suppress the main intestinal spoilage products, indole, and tryptamine, which are metabolites of tryptophan found in serum. Although the mechanism of this action is not clear, it is considered that the product of the present invention has a good effect on the intestinal flora and suppresses or prevents the production of toxic substances in the intestine. By co-administering the product of the present invention and tryptophan, the absorption rate of tryptophan in the small intestine is increased, and further administration of the product of the present invention suppresses the generation of ammonia to normalize the action of the intestinal flora, and fatty acid, It was suggested that the absorption rate of amino acids in the small intestine is increased and the production of amines from other amino acids is suppressed. This means that the utilization efficiency of nutrients in the intestine is obviously improved, and further the results suggesting the promotion of hepatic protein resynthesis have been revealed.

Claims (1)

[Claims] Mushroom (scientific name: Agaricus bispor
us) Inhibitor of intestinal toxic spoilage products (tryptamine, indole) whose main component is an extract of an aqueous solution of fruiting bodies